Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from the USFDA to market Nystatin Topical Powder USP, 100,000 units per gram.
The drug will be produced at the Nesher Pharmaceuticals’ manufacturing facility located at St. Louis, MO, USA. Nystatin Topical Powder is an antifungal antibiotic used to treat skin infections caused by yeast.
The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
